Table 1.
Baseline patient and clinical characteristics for all patients and for patients with HCC and CCA/cHCC-CCA.
| Characteristic | N |
All (N = 991) |
HCC (N = 521) |
CCA/cHCC-CCA (N = 471) |
p-value2 |
|---|---|---|---|---|---|
| Age, IQR | 99 | 69 (63 – 76) | 70 (64 – 75) | 69 (63 – 77) | 0.85 |
| Sex (Male) | 99 | 70 (71) | 40 (77) | 30 (64) | 0.15 |
| Ethnicity | 99 | 0.84 | |||
| White | 89 (90) | 46 (88) | 43 (92) | ||
| Black | 8 (8) | 5 (10) | 3 (6) | ||
| Asian | 2 (2) | 1 (2) | 1 (2) | ||
| ECOG | 99 | 0.8 | |||
| 0 | 38 (38) | 19 (37) | 19 (40) | ||
| 1 | 41 (42) | 22 (42) | 19 (40) | ||
| 2 | 19 (19) | 10 (19) | 9 (20) | ||
| 3 | 1 (1) | 1 (2) | 0 (0) | ||
| AFP (ng/mL), IQR3 | 74 | 5.6 (2.8 – 18.5) | 7.7 (3.0 – 48.8) | 3.5 (2.0 – 6.2) | 0.004 |
| Bilirubin, Total (mg/dL), IQR3 | 97 | 0.5 (0.4 – 0.9) | 0.7 (0.4 – 1.0) | 0.5 (0.4 – 0.6) | 0.02 |
| Albumin (g/dL), IQR3 | 97 | 3.7 (3.3 – 4.0) | 3.7 (3.3 – 4.0) | 3.7 (3.3 – 4.0) | 0.82 |
| BCLC | 524 | ||||
| A | See HCC | 3 (6) | NA | ||
| B | See HCC | 8 (15) | NA | ||
| C | See HCC | 40 (77) | NA | ||
| D | See HCC | 1 (2) | NA | ||
| Child-Pugh Class | 505 | 0.56 | |||
| A | 45 (90) | 41 (91) | 4 (80) | ||
| B | 4 (8) | 3 (7) | 1 (20) | ||
| C | 1 (2) | 1 (2) | 0 (0) | ||
| ALBI Grade | 99 | 0.74 | |||
| 1 | 43 (44) | 24 (46) | 19 (42) | ||
| 2 | 51 (53) | 27 (52) | 24 (54) | ||
| 3 | 3 (3) | 1 (2) | 2 (4) | ||
| T Stage6 | 99 | <0.001 | |||
| 1 | 25 (25) | 3 (6) | 22 (47) | ||
| 2 | 40 (41) | 24 (46) | 16 (34) | ||
| 3 | 12 (12) | 10 (19) | 2 (4) | ||
| 4 | 21 (21) | 15 (29) | 6 (13) | ||
| X | 1 (1) | 0 (0) | 1 (2) | ||
| N Stage6 | 99 | 0.053 | |||
| 0 | 91 (92) | 51 (98) | 40 (86) | ||
| 1 | 5 (5) | 1 (2) | 4 (8) | ||
| X | 3 (3) | 0 (0) | 3 (6) | ||
| M Stage6 | 99 | 0.26 | |||
| 0 | 95 (96) | 51 (98) | 44 (94) | ||
| 1 | 4 (4) | 1 (2) | 3 (6) | ||
| Group Stage6 | 99 | <0.001 | |||
| I | 22 (22) | 3 (6) | 19 (40) | ||
| II | 38 (39) | 23 (44) | 15 (32) | ||
| III | 19 (19) | 10 (19) | 9 (19) | ||
| IV | 20 (20) | 16 (31) | 4 (9) | ||
| Liver Lesion Number | 99 | 0.052 | |||
| 1 | 69 (70) | 31 (60) | 38 (81) | ||
| 2 | 13 (13) | 7 (13) | 6 (13) | ||
| 3 | 10 (10) | 8 (15) | 2 (4) | ||
| >3 | 7 (7) | 6 (12) | 1 (2) | ||
| Tumor Size (cm) | 89 | 2.9 (2.0 – 4.7) | 3.2 (2.3 – 4.9) | 2.8 (1.7 – 4.1) | 0.12 |
| Portal Vein Involvement | 99 | 18 (18) | 11 (21) | 7 (15) | 0.42 |
| Systematic Therapy | 99 | 32 (32) | 3 (6) | 29 (62) | <0.001 |
5-FU, 5-Fluorouracil; AFP, Alpha-Fetoprotein; ALBI, Albumin-bilirubin; BCLC, Barcelona Clinic Liver Cancer; cHCC-CCA, combined biphenotypic hepatocellular-cholangiocarcinoma; ECOG, Eastern Cooperative Oncology Group; HCC, hepatocellular carcinoma.
1
Statistics presented: Median (IQR); n (%).
2
Statistical tests performed: Wilcoxon rank-sum test; chi-square test of independence.
3
Pre-treatment laboratory values.
4
BCLC is only available for patients with HCC.
5
Child-Pugh Class is only available for patients with cirrhosis.
6
UNOS Staging for patients with HCC and AJCC 8th ed. Staging for patients with cholangiocarcinoma and biphenotypic tumor.